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OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by
evaluating serum oxidative status and prolidase activity.
METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total
antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil
citrate.
RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and
prolidase were 1.1¡0.0 vs. 1.6¡0.0 mmol H2O2 Eq/L, 10.3¡1.1 vs. 6.9¡1.2 mmol H2O2 Eq/L, and 236.4¡19.5 vs.
228.2¡19.2 U/L, respectively (p,0.0001 for all).
CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of
PDE5 inhibitor in patients with erectile dysfunction.
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INTRODUCTION
Although phosphodiesterase type 5 (PDE5) inhibitors
were initially approved for the treatment of male erectile
dysfunction (ED), their clinical spectrum has expanded
owing to the enormous advances that have been made
during the past decade. In preliminary studies, this progress
in clinical practice was not restricted to human sexuality,
either male or female, other than male ED, but extended to
systemic disorders such as cardiovascular conditions and
diabetes mellitus, owing to the beneficial effects of PDE5
inhibitors on endothelial functions, depression, pulmonary
hypertension, pre-eclampsia, inflammation, chronic heart
failure and renal insufficiency, hypertensive disorders, and
even to cancer treatment, owing to induction of an apoptotic
mechanism.1-5
It is well known that oxidative stress leads to impaired
vasodilatation of the coronary, pulmonary, and peripheral
vascular beds.6 There is limited information about the effect
of PDE5 inhibitors on the serum oxidative mechanism,
although its effect in restoring endothelial nitric oxide,
which results in vasodilatation and inhibition of chemotaxis
and platelet aggregation, is well known.7 In some studies
sildenafil citrate has been shown to have protective effects
against oxidative stress by inhibiting free radical formation
and supporting antioxidant redox systems, and it is
suggested that this reduced oxidative stress results in
improvement of endothelial function.8,9 We have shown
that serum prolidase activity is significantly associated with
the presence and severity of vasculogenic ED, and elevated
serum prolidase activity may be an independent predictor
of ED.10 However, to our knowledge, the effect of the PD5
inhibitors on serum prolidase enzymes, which are closely
related to serum oxidative status and endothelial functions,
has not yet been documented.
Prolidase is a cytosolic enzyme, necessary for specific
splitting of imidodipeptides with proline or hydroxyproline
at their C-terminals, and has a major role in collagen
turnover and cell growth.10,11 The relationship between
collagen and prolidase activity was observed during a study
of fibrotic processes, where an increase in prolidase acti-
vity was accompanied by an increase in tissue collagen
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deposition.11 The negative effect of free radicals is mediated
by degradative agents such as proteolytic enzymes and the
final step of collagen degradation is mediated by proli-
dase.12 Surazynski et al. noted that prolidase may also have
a role in angiogenesis since prolidase deficiency is asso-
ciated with angiopathy.13
In this study, we investigated the acute effects of PD5
inhibitor (tadalafil citrate 20 mg) as an on-demand use PDE5
inhibitor at peak serum level on serum oxidative status and
prolidase enzyme activities in patients with ED.
MATERIAL AND METHODS
Subjects
The study included 36 patients with clinically documented
ED (aged 37–59 years, mean¡SD 49.5¡6.5) who had been
followed up at the department of urology, had a stable
monogamous relationship with a female partner, and for
whom PDE5 inhibitor treatment had been recently proposed.
Controls comprised 30 people with no ED (aged 35–58 years,
mean¡SD 50.1¡6.7). The study was approved by Harran
University’s Institutional Review Board and was performed
in accordance with the ethical standards laid down in the
1975 and 1983 Declaration of Helsinki. The participants were
informed about the study protocol and written consent was
obtained from all participants before the start of the study.
All patients provided a detailed sexual history, and
underwent a physical examination, blood chemistry and
endocrine assay, and color Doppler ultrasonography during
pharmacologically induced and sexually stimulated erec-
tion. Patients with angina during intercourse, unstable
angina or any other evidence of recently diagnosed
coronary artery disease, poorly controlled blood pressure
or orthostatic hypotension, congestive heart failure, arrhyth-
mia, significant renal or hepatic dysfunction, anemia, and
patients aged .60 years were excluded. Additionally,
patients who had been receiving any medication that had
an effect on serum oxidative status (vitamin E, vitamin C, L-
arginine, etc) within the past 4 weeks or who had under-
gone pelvic surgery were also excluded. All blood samples
for determination of total antioxidant status (TAS), total
oxidant status (TOS), and prolidase activities were collected
from the subjects just before and 2 h after 20 mg oral
tadalafil citrate (CialisH, Lilly Inc, Istanbul, Turkey) admin-
istration—that is, at the peak plasma level, which occurs at
approximately 2 h after administration. During these 2 h,
subjects remained at rest under clinic conditions and were
not allowed to consume anything except water. Blood
sample collections were performed in an air-conditioned
consulting room at a temperature of 23–25 C˚.
Measurement Total Oxidant–Antioxidant Status
An automated colorimetric measurement method was
used for the analysis of TOS.14 The results were expressed as
mmol H2O2 Eq/L. TAS was measured by an automated
measurement method in which hydroxyl radicals are
produced via the Fenton reaction and the colored dianisi-
dinyl radical cations consequently produced in the reaction
medium of the assay can be measured by absorbance.15 The
results were expressed as mmol Trolox Eq/L.
Measurement of Prolidase Activity
Serum was diluted 40-fold with 25 mmol/L Mn2+,
40 mmol/L Trizma HCl buffer (pH 8.0) and preincubated
at 37 C˚ for 2 h. The reaction mixture containing 30 mmol/L
Gly-Pro, 40 mmol/L Trizma HCl buffer (pH 8.0), and 100 mL
of preincubation serum in 1 mL was incubated at 37 C˚
for 30 min. The reaction was stopped by adding 0.5 mL
20% trichloroacetic acid solution. The supernatant was
used for measurement of proline by the method proposed
by Myara et al.,16 which is a modification of Chinard’s
method.17
Statistical Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS Inc, Chicago, IL, USA)
version 11.0 for Windows. Results were expressed as
mean¡SD for all continuous variables. Differences between
control, pre- and post-medication groups were assessed
using an independent samples t-test. Differences between
pre- and post-medication groups were assessed using a
paired sample t-test. A value of p,0.05 was considered
statistically significant.
RESULTS
Demographic characteristics and risk factors for ED of the
patients are given in Table 1. The serum samples of 30 control
cases and 36 patients with ED (body mass index; range 22.0–
29.8 kg/m2, mean¡SD 27.0¡2.2 kg/m2), before and after
tadalafil citrate administration (120 min), were analyzed. For
controls, serum levels of TOS, TAS, and prolidase were
4.37¡0.9 mmol H2O2 Eq/L, 1.83¡0.2 mmol Trolox Eq/L, and
218.09¡17.5 U/L, respectively. The mean basal and post
tadalafil citrate administration serum parameters (TOS, TAS,
and prolidase) of the patients are summarized in Table 2.
While the mean basal serum level of TAS and TOS were
1.1¡0.0 and 10.3¡1.1 mmol H2O2 Eq/L, the post tadalafil
citrate values were 1.6¡0.0 and 6.9¡1.2 mmol Trolox Eq/L,
respectively. Both reductions in TOS and increases in TAS
serum values were significant (p,0.0001). The mean proli-
dase activity under the influence of the drug was 228.2¡
19.2 U/L, in comparison with the basal value of 236.4¡
19.5 U/L—a significant reduction (p,0.0001).
DISCUSSION
This study aimed to document the acute effects of tada-
lafil citrate at peak serum levels on the vascular system by
evaluating serum oxidative–antioxidative status, and proli-
dase enzyme activities. Tadalafil citrate was chosen for this
study, because it has the longest half-life of the PDE5
Table 1 - Demographic characteristics and risk factors for
erectile dysfunction of the patients and control cases.
Control (n = 30) Patients (n = 36) p Value
Demographic characteristics
Age (years) (mean
¡SD)
50.1¡6.7 49.5¡6.5 .0.05
BMI (kg/m2) 28.0¡2.9 27.0¡2.2 .0.05
Risk factors n (%)
Smoking 12 (40) 14 (39)
Depression - 2 (6)
Diabetes mellitus 8 (27) 12 (33)
Hypertension 13 (43) 12 (33)
Chronic heart failure 5 (17) 7 (19)
Hypercholesterolemia 4 (13) 7 (19)
BMI, body mass index.
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inhibitors, making it an ideal candidate when switching
from on-demand use to its use as a prophylactic drug for
any indication in the future. The safety of the drug will be
important for regular long-term users.
It has been suggested that oral vasoactive pharmacother-
apy, such as PDE5 inhibitor drugs, may provide vasculo-
protective benefits for cardiovascular disease as well as for
vasculogenic ED.18 Reduced serum oxidative stress is
thought to be the foundation of this mechanism. More-
over, in support of this theory from the opposite side,
oxidative stress has been shown to have a role in the
development and progression of atherosclerosis.19 It was
claimed, in a placebo-controlled study, that 100 mg silde-
nafil improved the serum oxidative status of subjects
without any health problems;8 this effect lasted for 1 day.
A further study reached the same conclusion in an animal
model of second-hand smoke-induced ED.9 Our results for
the oxidative status of the patients with ED support these
findings for tadalafil citrate and, additionally, we think that
the reduced serum oxidative stress may last for more than a
day because tadalafil citrate has a longer serum half-life
than sildenafil. On the contrary, in a recent study, Burnett et
al. found no effect of sildenafil on serum oxidative status in
diabetic patients with ED receiving short-term treatment.18
It should be remembered that all three PDE5 inhibitors have
similar oxidative activity.19 However, to our knowledge,
this is the first clinical study that has evaluated the relation
between tadalafil citrate and serum oxidative–antioxidative
status, showing decreasing TOS and increasing TAS values
with treatment.
Prolidase is a highly specific peptidase that has an
important functional role in all human tissues and cells.
High prolidase activity has been reported in the brain, heart,
liver, muscle and, especially, in the kidney. Hereditary
prolidase deficiency—a multisystemic disorder—is charac-
terized by a wide spectrum of clinical manifestations,
including skin ulcers, mental retardation, and susceptibility
to infections. Oxidative stress results in collagen degrada-
tion and this process is mediated by prolidase.12 Moreover,
the degree of severity of oxidative stress is directly related
to the inhibition of collagen production, and prolidase
is thought to be the target enzyme of this process.20 Our
study showed that tadalafil citrate significantly reduced
prolidase activity at the peak serum level. This might be due
to reduced degradation activity, possibly caused by reduced
serum oxidative stress. In addition, reduced prolidase
activity also confirms the reduced oxidative stress under
the action of tadalafil citrate—a topic still debated in the
literature.
Fibrosis of the corpora cavernosa and the media of penile
arteries, involving loss of smooth muscle cells, is a common
process that underlies most cases of vasculogenic ED.21 The
concept that progressive fibrosis of the smooth muscle tissue
within the penile corpora cavernosa is responsible for the
vasculogenic ED associated with diabetes, ageing, heavy
smoking, and pelvic surgery, has gained support over the
past decade.22 From a functional perspective, this fibrotic
process leads to a decrease in the compliance of the corporal
tissue after stimulation by the nitric oxide/cyclic guanosine
monophosphate system. This inability of the corporal tissue
to relax sufficiently to occlude the regressing subtunical veins
occurs in most patients with ED23-26 and is termed
venous leakage or corporal veno-occlusive dysfunction.
Therefore, the study of fibrosis may provide a unifying view
of the vasculogenic disorders affecting the penis. Profibrotic
factors, the excessive deposit of collagen fibers and other
extracellular matrix, the appearance of a synthetic cell pheno-
type in smooth muscle cells or the onset of a fibroblast–
myofibroblast transition, and in the case of the corporal or
penile arterial tissue, the reduction of the smooth muscle
cellular compartment underlies vasculogenic ED. This
histopathology leads either to localized plaques or nodules
in penile tissue, or to the diffuse fibrosis causing impairment
of tissue compliance that underlies corporal veno-occlusive
dysfunction and arteriogenic ED. The antifibrotic role of the
sustained stimulation of the nitric oxide/cyclic guanosine
monophosphate pathway in the penis and its possible
relevance to exogenous and endogenous stem cell differ-
entiation may explain the collagen biosynthesis. The relation-
ship between collagen and prolidase activity was observed
during fibrotic processes, where an increase in prolidase
activity was accompanied by increase in tissue collagen
deposition.27 The negative effect of free radicals is mediated
by degradative agents such as proteolytic enzymes and the
last step of collagen degradation is mediated by prolidase.12
Surazynski et al. pointed out that prolidase may also have
a role in angiogenesis as prolidase deficiency is associated
with angiopathy.13 Oxidative stress resulted in collagen
degradation and this process is mediated by prolidase.12
Moreover the degree of severity of oxidative stress is directly
related to the inhibition of collagen production, and proli-
dase is thought to be the target enzyme of this process.28
Yildiz et al. showed that increased serum prolidase activity
was significantly associated with the presence and severity of
coronary artery disease.29 In accordance with their study we
have shown that serum prolidase activity is significantly
associated with the presence and severity of vasculogenic ED,
and elevated serum prolidase activity may be an indepen-
dent predictor of ED.10 In addition, it was suggested that
hypertension and its duration is associated with increased
serum prolidase activity and might be useful as a marker for
the follow-up of hypertensive patients.11
Table 2 - Mean serum total antioxidant status, total oxidant status and prolidase enzyme activities of the patients
(before and after tadalafil citrate) and control cases.
Patient (n = 36) p Value
Control (n = 30) BTC ATC p1 p2 p3
TOS (mmol H2O2 Eq/L) 4.37¡ 0.9 10.3¡1.1 6.9¡1.2 ,0.0001 ,0.0001 ,0.0001
TAS (mmol Trolox Eq/L) 1.83¡0.2 1.1¡0.0 1.6¡0.0 ,0.0001 ,0.0001 ,0.0001
Prolidase (U/L) 218.09¡17.5 236.4¡19.5 228.2¡19.2 ,0.0001 ,0.0001 ,0.0001
ATC, after tadalafil citrate administration; BTC, before tadalafil citrate administration; TAS, total antioxidant status; TOS, total oxidant status.
p1, independent samples t-test for control and patient before tadalafil citrate; p2, independent samples t-test for control and patient after tadalafil
citrate; p3; paired samples t-test for patient before and after tadalafil citrate.
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Several potential limitations of this study should be
considered. First, is the cross-sectional design of this study.
Usually, to assess the effect of any agent on a molecule the
investigation should be based on a chronic treatment set-up
but in this study the acute effect of the PDE5 inhibitor was
investigated. To extend the findings of our study, assess-
ment of serum prolidase activity in endothelial cells, and
evaluation of the association of serum prolidase activity
with the presence and extent of atherosclerosis in other
regions of the arterial system would better clarify the
pathophysiological role of prolidase activity in endothelial
dysfunction. Evaluation of the association of serum proli-
dase activity with the extent of endothelial ischemia would
identify the role of endothelial ischemia in increased
collagen turnover in patients with vasculogenic ED. Finally,
measurement of serum oxidative status and prolidase
enzyme activities after daily treatment with PDE5 inhibitor
would have added to the value of this study, but this was
beyond the scope of this present work.
In conclusion, the results of this preliminary study
confirm the beneficial acute effects of PD5 inhibitor in
patients with ED by evaluating serum oxidative status and
prolidase activity. However, further clinical long-term
studies of this issue, particularly including groups at high
risk, should be carried out.
REFERENCES
1. Frajese GV, Pozzi F. New achievement and novel therapeutic applica-
tions of PDE5 inhibithors in older males. J Endocrinol Invest. 2005;28:
45-50.
2. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular
disease. Am J Cardiol. 2003;92:26-36, doi: 10.1016/S0002-9149(02)03368-4.
3. Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The
effect of sildenafil on the altered thoracic aorta smooth muscle responses
in rat pre-eclampsia model. Eur J Pharmacol. 2008;589:180-7, doi: 10.1016/
j.ejphar.2008.04.034.
4. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiester-
ase 5 and its inhibitors in carcinoma cells and pulmonary/cardio-
vascular vessels. Curr Top Med Chem. 2007;7:437-54, doi: 10.2174/
156802607779941198.
5. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ.
Phosphodiesterase type 5 inhibition reverses impaired forearm exer-
cise-induced vasodilatation in hypertensive patients. J Hypertens. 2008;
26:501-7, doi: 10.1097/HJH.0b013e3282f382ff.
6. Eleuteri E, Magno F, Gnemmi I, Carbone M, Colombo M, La Rocca G,
et al. Role of oxidative and nitrosamine stress biomarkers in chronic
heart failure. Front Biosci. 2009;14:2230-7, doi: 10.2741/3375.
7. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial
dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res. 2007;4:89-102,
doi: 10.3132/dvdr.2007.026.
8. Perk H, Armagan A, Nazirog˘lu M, Soyupek S, Hoscan MB, Su¨tcu¨ R, et al.
Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant
effect in the blood of men. J Clin Pharm Ther. 2008;33:635-40, doi: 10.
1111/j.1365-2710.2008.00962.x.
9. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal
S, et al. Sildenafil inhibits superoxide formation and prevents endothelial
dysfunction in a mouse model of secondhand smoke induced erectile
dysfunction. J Urol. 2009;181:899-906, doi: 10.1016/j.juro.2008.10.062.
10. Savas M, Yeni E, Celik H, Ciftci H, Utangac M, Oncel H, et al. The
association of serum prolidase activity and erectile dysfunction. J Androl.
2010;31:146-54, doi: 10.2164/jandrol.109.008631.
11. Demirbag R, Yildiz A, Gur M, Yilmaz R, Elc¸i K, Aksoy N. Serum
prolidase activity in patients with hypertension and its relation with left
ventricular hypertrophy. Clin Biochem. 2007;40:1020-5, doi: 10.1016/j.
clinbiochem.2007.05.015.
12. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M.
Increased oxidative stress and its relation with collagen metabolism in
knee osteoarthritis. Rheumatol Int. 2007;27:339-44, doi: 10.1007/s00296-
006-0247-8.
13. Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow K, Liu Y,
et al. Extracellular matrix and HIF-1 signaling: the role of prolidase.
Int J Cancer. 2008;122:1435-40, doi: 10.1002/ijc.23263.
14. Erel O. A new automated colorimetric method for measuring total oxi-
dant status. Clin Biochem. 2005;38:1103-11, doi: 10.1016/j.clinbiochem.
2005.08.008.
15. Erel O. A novel automated method to measure total antioxidant response
against potent free radical reactions. Clin Biochem. 2004;37:112-9, doi: 10.
1016/j.clinbiochem.2003.10.014.
16. Myara I, Cosson C, Moatti N, Lemonnier A. Human kidney prolidase
purification, preincubation properties and immunological reactivity.
Int J Biochem. 1994;26:207-14, doi: 10.1016/0020-711X(94)90147-3.
17. Chinard FP. Photometric estimation of proline and ornithine. J Biol
Chem. 1952;199:91–5.
18. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum
biomarker measurements of endothelial function and oxidative stress
after daily dosing of sildenafil in type 2 diabetic men with erectile
dysfunction. J Urol. 2009;181:245-51, doi: 10.1016/j.juro.2008.09.005.
19. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology.
2006;13:129-42, doi: 10.1016/j.pathophys.2006.05.002.
20. Speranza L, Franceschelli S, Pesce M, Vinciguerra I, De Lutiis MA, Grilli
A, et al. Phosphodiesterase type-5 inhibitor and oxidative stress.
Int J Immunopathol Pharmacol. 2008;21:879-89.
21. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009;6
(suppl 3):353-62, doi: 10.1111/j.1743-6109.2008.01195.x.
22. Kovanecz I, Nolazco G, Ferrini MG, Toblli JE, Heydarkhan S, Vernet D,
et al. Early onset of fibrosis within the arterial media in a rat model of
type 2 diabetes mellitus with erectile dysfunction. BJU Int. 2009;103:1396-
404, doi: 10.1111/j.1464-410X.2008.08251.x.
23. Luo H, Goldstein I, Udelson D. A three-dimensional theoretical model of
the relationship between cavernosal expandability and percent caverno-
sal smooth muscle. J Sex Med. 2007;4:644–5, doi: 10.1111/j.1743-6109.
2007.00492.x.
24. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporal venous
leakage in impotent men. J Urol. 1988;140:69–71
25. Metro MJ, Broderick GA. Diabetes and vascular impotence: does insulin
dependence increase the relative severity? Int J Impot Res. 1999;11:87–9,
doi: 10.1038/sj.ijir.3900387.
26. Lue TF. Veno-occlusive dysfunction of corpora cavernosa: comparison of
diagnostic methods. J Urol. 1996;155:786–7.
27. Verit FF, Geyikli I, Yazgan P, Celik A. Correlations of serum prolidase
activity between bone turnover markers and mineral density in
postmenopausal osteoporosis. Arch Gynecol Obstet. 2006;274:133-7,
doi: 10.1007/s00404-006-0148-9.
28. Sienkiewicz P, Pałka M, Pałka J. Oxidative stress induces IGF-I receptor
signaling disturbances in cultured human dermal fibroblasts. A possible
mechanism for collagen biosynthesis inhibition. Cell Mol Biol Lett.
2004;9:643-50.
29. Yildiz A, Demirbag R, Yilmaz R, Gur M, Altiparmak IH, Akyol S, et al.
The association of serum prolidase activity with the presence and
severity of coronary artery disease. Coron Artery Dis. 2008;19:319-25,
doi: 10.1097/MCA.0b013e32830042ba.
Effects of PDE5 inhibitors on vasculogenic ED
Savas M et al.
CLINICS 2010;65(12):1311-1314
1314
